View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 21, 2020

RedHill Biopharma partners with NIAID for potential Covid-19 drug

Israel-based RedHill Biopharma has partnered with the US National Institute of Allergy and Infectious Diseases (NIAID) to study its RHB-107 (upamostat, WX-671) drug candidate in non-clinical tests for the treatment of Covid-19.

Israel-based RedHill Biopharma has partnered with the US National Institute of Allergy and Infectious Diseases (NIAID) to study its RHB-107 (upamostat, WX-671) drug candidate in non-clinical tests for the treatment of Covid-19.

RHB-107 is a serine protease inhibitor active against various human trypsins and other related serine proteases.

It is an experimental drug evaluated in more than 300 people across ten clinical studies, including Phase I and II trials for cancer treatment.

Data from these studies validated the drug candidate’s safety and tolerability in humans said the company.

The company expects that serine proteases inhibition, including trypsins, to block viral attachment and replication while mitigating lung damage from viral pneumonia.

RedHill Biopharma medical director Terry Plasse said: “RHB-107 is the second investigational drug that RedHill is evaluating for Covid-19, underscoring our commitment to the global efforts to develop a treatment for patients with this disease.

“This new agreement will facilitate pre-clinical evaluation of RHB-107 as a potential Covid-19 treatment.”

The company is also assessing its investigational drug, opaganib (Yeliva, ABC294640) to potentially treat Covid-19.

Opaganib is an oral, sphingosine kinase-2 (SK2) selective inhibitor said to possess anticancer, anti-viral and anti-inflammatory properties.

The company recently submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA) to conduct a Phase IIa clinical trial of opaganib in up to 60 adults hospitalised due to Covid-19 and pneumonia.

A compassionate use programme for opaganib is ongoing in Israel, where many patients have been treated so far.

The drug also obtained authorisation from the Italian National Institute for Infectious Diseases and Central Italian Ethics Committee for an expanded access programme in Covid-19.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU